Scientifically reviewed by Dr Stephan Hansberg
GLOW vs KLOW vs WOLVERINE: peptide blends compared
Exact compositions of the GLOW, KLOW and WOLVERINE research pens, what each compound is studied for in the published literature, how the blend names vary between sellers, and where each certificate stands.
Key takeaways
- •WOLVERINE, GLOW and KLOW are nested blends: WOLVERINE is BPC-157 plus TB-500, GLOW adds GHK-Cu, and KLOW adds KPV to GLOW.
- •In Celyfe pens the amounts are WOLVERINE 30mg, GLOW 105mg and KLOW 120mg per 3ml cartridge, with the same 15mg of BPC-157 and 15mg of TB-500 in each.
- •The names are market conventions, not standards: other sellers use different ratios, for example GLOW vials commonly sold as 50, 10 and 10mg.
- •Each component has its own research literature, mostly in cell and animal models; no published trial has studied these blends as defined combinations.
- •WOLVERINE has a published batch COA (C26071, 99% by HPLC); GLOW and KLOW certificates are being re-issued and will be listed in the COA library.
The short answer
WOLVERINE, GLOW and KLOW are three related peptide blends that build on each other: WOLVERINE combines BPC-157 and TB-500, GLOW adds the copper peptide GHK-Cu, and KLOW adds the tripeptide KPV on top of GLOW. The difference between them is simply which compounds are included and in what amounts. The names are supplier conventions rather than defined standards, so the ratios inside a product called GLOW or KLOW vary from seller to seller.
This guide compares the three as Celyfe supplies them, explains what each compound has been studied for, and shows how to check a blend you are comparing against.
Exact compositions
All three Celyfe pens use a pre-filled 3ml cartridge, so the concentration of each compound is its mass divided by 3ml. BPC-157 and TB-500 are present at the same amount in all three.
| Compound | WOLVERINE | GLOW | KLOW |
|---|---|---|---|
| BPC-157 | 15mg (5mg/ml) | 15mg (5mg/ml) | 15mg (5mg/ml) |
| TB-500 | 15mg (5mg/ml) | 15mg (5mg/ml) | 15mg (5mg/ml) |
| GHK-Cu | None | 75mg (25mg/ml) | 75mg (25mg/ml) |
| KPV | None | None | 15mg (5mg/ml) |
| Total per cartridge | 30mg | 105mg | 120mg |
| Total concentration | 10mg/ml | 35mg/ml | 40mg/ml |
| Published COA | Batch C26071, 99% (HPLC) | Being re-issued | Being re-issued |
What each compound is studied for
Each blend component has its own body of published research. Almost all of it is preclinical, meaning cell culture and animal models, and none of it establishes effects of the blends themselves. The summaries below describe research areas, not outcomes in people.
- BPC-157: a synthetic 15-amino-acid peptide derived from a protein in gastric juice. It has been studied mainly in rodent models of gastrointestinal, tendon, ligament, muscle and bone injury, and in relation to angiogenesis and growth-factor signalling. Much of the literature comes from one research group in Zagreb.
- TB-500: a synthetic peptide from the actin-binding region of thymosin beta-4, a 43-amino-acid protein that sequesters G-actin. Thymosin beta-4 has been studied in cell and animal models for cell migration, angiogenesis and tissue repair.
- GHK-Cu: the tripeptide glycyl-histidyl-lysine bound to copper. It has been studied in cell and animal models and in topical cosmetic research, with gene-expression analyses describing effects on extracellular matrix and collagen-related genes in vitro.
- KPV: the lysine-proline-valine tripeptide from the C-terminus of alpha-MSH. It has been studied in cell and mouse models of intestinal inflammation, including work showing uptake through the PepT1 transporter.
How the blend names are used across the market
Because GLOW, KLOW and WOLVERINE are informal market names, the same name can describe quite different products. A GLOW vial is widely sold as 70mg of lyophilised powder in a 50, 10 and 10mg arrangement, with GHK-Cu as the largest component and BPC-157 and TB-500 at 10mg each. The Celyfe GLOW pen uses 75mg GHK-Cu with 15mg each of BPC-157 and TB-500, 105mg in total, in solution.
WOLVERINE-type blends are often labelled with shorthand such as 10/10 or 5/5, meaning milligrams of BPC-157 and TB-500. KLOW products add KPV, but the KPV amount, and whether the other components match the same seller's GLOW, varies.
The practical rule is to ignore the name and read the label: which compounds, how many mg of each, in what volume, and whether the certificate quantifies each component separately. Our guide to peptide blends explains how to read these labels in detail.
| Product as sold | Format | GHK-Cu | BPC-157 | TB-500 | KPV | Total |
|---|---|---|---|---|---|---|
| Common GLOW vial (market example) | Lyophilised powder | 50mg | 10mg | 10mg | None | 70mg |
| Celyfe GLOW pen | 3ml solution | 75mg | 15mg | 15mg | None | 105mg |
| Celyfe KLOW pen | 3ml solution | 75mg | 15mg | 15mg | 15mg | 120mg |
| Celyfe WOLVERINE pen | 3ml solution | None | 15mg | 15mg | None | 30mg |
Why the ratios differ
There is no pharmacopoeial monograph or published standard for any of these blends, so each manufacturer chooses its own amounts. Ratios are usually set by convention, by the cost of each compound, by solubility, and by the format: a lyophilised vial has to hold a mass that reconstitutes cleanly, while a solution cartridge has a fixed volume and a concentration limit for each compound.
This is why two products with the same name cannot be compared on price alone. Compare cost per mg of each component and check that each component is quantified on the certificate.
Certificate status
Celyfe publishes batch certificates from the independent laboratory Analiza Bialek in Wroclaw, Poland, tested by HPLC. The WOLVERINE certificate for batch C26071, dated 2 October 2026, reports 99% purity. GLOW and KLOW certificates are being re-issued; they will be listed in the COA library at /coa when published, and this page does not state results for them until then.
For any blend from any seller, a useful certificate names the batch, the laboratory, the method and the date, and reports each component separately rather than one combined figure.
Where Celyfe fits
All three blends are supplied as pre-filled, pre-mixed 3ml cartridges for the Celyfe precision pen, shipped worldwide cold-chain and tracked, dispatched within 1 to 2 working days, and stored at 2 to 8 °C (do not freeze). See /products/wolverine-pen, /products/glow-pen and /products/klow-pen, and the Strength Index at /strength-index.
Sources
- Seiwerth S, Rucman R, Turkovic B et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 2018. PMID 29998800.
- Goldstein AL, Hannappel E, Sosne G et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, January 2012. PMID 22074294.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, July 2018. PMID 29986520.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, January 2008. PMID 18061177.
- Resident. The GLOW Peptide Blend: Why Everyone Is Searching for It, and What the Science Says. 25 September 2026 (typical 50, 10 and 10mg vial composition).
Research use only
Celyfe supplies research peptides for laboratory and research use only. Nothing on this page is guidance on use in humans or animals.
Research updates
Peptide research and testing, in your inbox
New batch certificates, regulation changes and a monthly digest of new published research on the compounds we cover. No spam, unsubscribe at any time.